Covid-19: Study on long-term antibody protection

Image source: PIRO4D from Pixabay (background) / Logo Rhineland Study © DZNE

News • After overcoming a Corona infection

Covid-19: Study on long-term antibody protection

Does overcoming a SARS-CoV-2 infection protect against reinfection? The “Rhineland Study”, a population-based study conducted by DZNE in the Bonn area, is now providing new findings in this regard.

Blood samples taken last year indicate that an important component of immunity – the levels of specific neutralizing antibodies against the coronavirus - had dropped in most of the study participants with a previous infection after four to five months. In some, antibody titers even fell below the detection limit. These results, published in the scientific journal “Nature Communications”, lay the groundwork for planned follow-up studies.

Between April and June 2020, around 5,300 adult Bonn residents were tested for antibodies against the SARS-CoV-2 coronavirus as part of the Rhineland Study - an ongoing DZNE study investigating population health. For this purpose, blood samples were taken and analyzed. If initial results were positive, these samples were subjected to further testing by means of a so-called “plaque reduction neutralization test” to ensure that the detected antibodies were specifically directed against SARS-CoV-2 - and not against other coronaviruses that, e.g., can trigger common colds. In these analyses, the team of the Rhineland Study cooperated with the Institute of Virology at the Charité - Universitätsmedizin Berlin.

portrait of monique breteler
Prof. Dr. Dr. Monique M.B. Breteler

Image source: DZNE / Dr. Antonio Schmandke

Antibodies are proteins produced by the immune system with which the human organism defends itself against pathogens. In 22 study participants, “neutralizing” and thus particularly effective antibodies, which directly prevent the entry of SARS-CoV-2 into cells, could be detected. This indicated previous contact with the virus. The majority of these individuals reported to have experienced only a mild or even asymptomatic course of the disease. They were retested in September 2020 - approximately four to five months after the initial blood sampling. In most of these persons antibody levels had waned, and in four individuals antibodies could not even be detected anymore. “These studies occurred during the first wave of the pandemic. The number of people who had already become infected at that time was therefore relatively low. In the meantime, we have a different situation,” Prof. Monique Breteler, head of the Rhineland Study, says. “Nonetheless, our results suggest that the widely used, just single-stage procedure for detecting SARS-CoV-2 antibodies by immunoassay is insufficient to reliably identify a passed infection. In any case, in our sample, only about one-third of the individuals who were positive by immunoassay actually had specific antibodies against SARS-CoV-2. This should be considered in immunity studies. In my view, a multistage testing procedure like the one we used is highly recommended.”

Ultimately, we want to help better understand why some people don’t even notice an infection and others become severely ill

Monique Breteler

These study data, however, do not allow direct inferences about the extent to which the waning of the antibodies affects the immune response, Dr. Ahmad Aziz, DZNE scientist and first author of the current publication, notes. “The decrease in antibodies seems to happen relatively quickly. However, the immune system has other tools to fight off pathogens. Antibodies are without doubt relevant, but they are only part of a larger arsenal. Other studies suggest that another component, which we call the cellular immune response, may persist despite dropping antibody levels.”

In fact, little is known about the durability of immunity to SARS-CoV-2 after infection. This may also depend on the particular variant of the virus. “On the part of the Rhineland Study, we intend to continue to track the development of the pandemic and its effects on the mental and physical health of the population. Our study is the basis for this.” Breteler says. “Ultimately, we want to help better understand why some people don’t even notice an infection and others become severely ill.”

To this end, the researchers are relying on the Rhineland Study’s data pool. Extensive health and lifestyle data are collected from all participants, for example on their blood counts, body composition, cardiovascular function, as well as sleep, diet and physical activity. “We have background information on all study participants that is relevant to health. This could be key to understanding the consequences of infection with SARS-CoV-2 and may help identifying risk factors,” Breteler says.

Source: German Center for Neurodegenerative Diseases (Deutsches Zentrum für Neurodegenerative Erkrankungen; DZNE)


Read all latest stories

Related articles


News • Autoimmune reaction study

Severe Covid-19 linked to increase in self-attacking antibodies

Hospitalized Covid-19 patients are substantially more likely to harbor autoantibodies — antibodies directed at their own tissues or at substances their immune cells secrete into the blood — than…


News • Championship with side effects

Football Euro: Study shows impact on Covid-19 infections

The European Football Championship in 2021 had an impact on the participating countries' coronavirus infections, a new study shows. However, the extent depended greatly on the initial situation.


News • Anosmia

Loss of smell after Covid-19: Researchers find key reason

After an infection with SARS-CoV-2, some people fail to recover their sense of smell. US researchers took a closer look at the olfactory nerve cells to find the reason for Covid-19-induced anosmia.

Related products

Beckman Coulter – Access Procalcitonin (PCT)


· Beckman Coulter – Access Procalcitonin (PCT)

Beckman Coulter Diagnostics
Fujifilm Wako – μTASWako i30


· Fujifilm Wako – μTASWako i30

FUJIFILM Wako Chemicals Europe GmbH
Mindray – CL-1000i/1200i Chemiluminescence Immunoassay System


Mindray Medical · Mindray – CL-1000i/1200i Chemiluminescence Immunoassay System

Shenzhen Mindray Bio-Medical Electronics Co., Ltd
Subscribe to Newsletter